Adicet Bio (ACET) Share-based Compensation (2017 - 2026)
Adicet Bio (ACET) posted quarterly Share-based Compensation of $1.3 million for Q1 2026, up 1152.88% year-over-year from $104000.0 in Q1 2025, and down 57.97% quarter-over-quarter from $3.1 million in Q4 2025.
Adicet Bio (ACET) Share-based Compensation (2017 - 2026) Analysis & Trends
Adicet Bio's Share-based Compensation history runs 10 years deep, the most recent figure standing at $1.3 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 1152.88% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $9.8 million (down 14.62% YoY), while the FY2025 annual figure was $104000.0, down 99.53% from the prior year.
- Share-based Compensation for Q1 2026 stood at $1.3 million, down from $3.1 million in the prior quarter.
- The five-year high for Share-based Compensation was $14.8 million in Q4 2022, with the low at $10000.0 in Q1 2023.
- The 5-year median for Share-based Compensation is $2.5 million (2025), against an average of $3.2 million.
- Peak annual rise in Share-based Compensation reached 2374.38% in 2023, while the deepest fall reached 99.1% in 2023.
- Adicet Bio's Share-based Compensation stood at $14.8 million in 2022, then plunged by 66.78% to $4.9 million in 2023, then declined by 23.17% to $3.8 million in 2024, then decreased by 17.84% to $3.1 million in 2025, then tumbled by 57.97% to $1.3 million in 2026.
- Business Quant data shows ACET's Share-based Compensation at $1.3 million in Q1 2026, $3.1 million in Q4 2025, and $2.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.47 Bn | 131.61 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.36 Bn | 78.37 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.16 Bn | 59.98 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.99 Bn | 53.85 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.74 Bn | 28.43 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.01 Bn | 9.61 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | - |
| 10 | Adicet Bio | 102.03 Mn | -16.16 Mn | - | 1.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.44 Mn |
| Jun 30, 2026 | 1.44 Mn |
| Mar 31, 2026 | 1.30 Mn |
| Mar 31, 2026 | 1.30 Mn |
| Dec 31, 2025 | 3.10 Mn |
| Dec 31, 2025 | 3.10 Mn |
| Sep 30, 2025 | 2.50 Mn |
| Sep 30, 2025 | 2.50 Mn |
| Jun 30, 2025 | 2.90 Mn |
| Jun 30, 2025 | 2.90 Mn |
| Mar 31, 2025 | 104,000.00 |
| Mar 31, 2025 | 104,000.00 |
| Dec 31, 2024 | 3.77 Mn |
| Dec 31, 2024 | 3.77 Mn |
| Sep 30, 2024 | 1.60 Mn |
| Sep 30, 2024 | 1.60 Mn |
| Jun 30, 2024 | 6.00 Mn |
| Jun 30, 2024 | 6.00 Mn |
| Mar 31, 2024 | 141,000.00 |
| Mar 31, 2024 | 141,000.00 |